Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 in T790M+ NSCLC after EGFR-TKI progression
NCT02442349Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02442349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442349.